Personalis, Inc. reported unaudited preliminary financial and operational results for Q4 and full year 2025.
Clinical test volume surged 41% in Q4 to 6,183 tests, exceeding internal growth targets.
The company ended the year with a strong cash position of approximately $240 million, enabling commercial expansion and innovation.
Clinical Volume Growth
Q4 saw a 41% increase in clinical test volume, signaling rising demand for ultrasensitive MRD testing.
Revenue Performance
Preliminary Q4 revenue expected to be $17 to $18 million, showing a stable financial position.
Medicare Coverage
Securing Medicare coverage for breast cancer surveillance validates the efficacy of Personalis' MRD technology.
- The achieved clinical volume growth of nearly 400% over the previous year demonstrates significant market adoption of Personalis' services.
- Securing pivotal Medicare coverage for breast cancer surveillance enhances commercial potential and market expansion opportunities.
Personalis's strong financial performance in 2025, marked by revenue stability and clinical volume growth, positions the company for further expansion and innovation in 2026.